Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Tiotropium increases PPARĪ³ and decreases CREB in cells isolated from induced sputum of COPD patients.

Holownia A, Mroz RM, Skopinski T, Kolodziejczyk A, Chyczewska E, Braszko JJ.

Adv Exp Med Biol. 2013;756:9-14. doi: 10.1007/978-94-007-4549-0_2.

PMID:
22836613
2.

Altered histone deacetylase activity and iNOS expression in cells isolated from induced sputum of COPD patients treated with tiotropium.

Holownia A, Mroz RM, Wielgat P, Skopinski T, Kolodziejczyk A, Sitko A, Chyczewska E, Braszko JJ.

Adv Exp Med Biol. 2013;788:1-6. doi: 10.1007/978-94-007-6627-3_1.

PMID:
23835951
3.

Tiotropium increases cytosolic muscarinic M3 receptors and acetylated H3 histone proteins in induced sputum cells of COPD patients.

Holownia A, Mroz RM, Skopinski T, Kielek A, Kolodziejczyk A, Chyczewska E, Braszko JJ.

Eur J Med Res. 2010 Nov 4;15 Suppl 2:64-7.

4.

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.

Farne HA, Cates CJ.

Cochrane Database Syst Rev. 2015 Oct 22;(10):CD008989. doi: 10.1002/14651858.CD008989.pub3. Review.

PMID:
26490945
5.

Siglec-8 in induced sputum of COPD patients.

Mroz RM, Holownia A, Wielgat P, Sitko A, Skopinski T, Chyczewska E, Braszko JJ.

Adv Exp Med Biol. 2013;788:19-23. doi: 10.1007/978-94-007-6627-3_3.

PMID:
23835953
6.

Tregs and HLA-DR expression in sputum cells of COPD patients treated with tiotropium and formoterol.

Holownia A, Wielgat P, Stasiak-Barmuta A, Kwolek A, Jakubow P, Szepiel P, Chyczewska E, Braszko JJ, Mroz RM.

Adv Exp Med Biol. 2015;839:7-12. doi: 10.1007/5584_2014_43.

PMID:
25315616
7.

Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.

Chong J, Karner C, Poole P.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009157. doi: 10.1002/14651858.CD009157.pub2. Review.

PMID:
22972134
8.

Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.

Hanania NA, Boota A, Kerwin E, Tomlinson L, Denis-Mize K.

Drugs. 2009 Jun 18;69(9):1205-16. doi: 10.2165/00003495-200969090-00005.

PMID:
19537837
9.

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.

van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ.

Chest. 2006 Mar;129(3):509-17.

PMID:
16537846
10.

Inhaled corticosteroids increase siglec-5/14 expression in sputum cells of COPD patients.

Wielgat P, Mroz RM, Stasiak-Barmuta A, Szepiel P, Chyczewska E, Braszko JJ, Holownia A.

Adv Exp Med Biol. 2015;839:1-5. doi: 10.1007/5584_2014_51.

PMID:
25252903
11.

Aclidinium bromide for stable chronic obstructive pulmonary disease.

Ni H, Soe Z, Moe S.

Cochrane Database Syst Rev. 2014 Sep 19;(9):CD010509. doi: 10.1002/14651858.CD010509.pub2. Review.

PMID:
25234126
12.

Indacaterol and tiotropium combination therapy in patients with chronic obstructive pulmonary disease.

Matsushima S, Inui N, Yasui H, Kono M, Nakamura Y, Toyoshima M, Shirai T, Suda T.

Pulm Pharmacol Ther. 2015 Feb;30:11-5. doi: 10.1016/j.pupt.2014.10.003. Epub 2014 Oct 30.

PMID:
25445929
13.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
14.

Multidetector-row computed tomography assessment of adding budesonide/formoterol to tiotropium in patients with chronic obstructive pulmonary disease.

Yasui H, Inui N, Furuhashi K, Nakamura Y, Uto T, Sato J, Yasuda K, Takehara Y, Suda T, Chida K.

Pulm Pharmacol Ther. 2013 Jun;26(3):336-41. doi: 10.1016/j.pupt.2013.01.005. Epub 2013 Jan 20.

PMID:
23340058
15.

A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.

Kern DM, Williams SA, Tunceli O, Wessman C, Zhou S, Pethick N, Elhefni H, Trudo F.

Int J Chron Obstruct Pulmon Dis. 2014 Jul 18;9:775-83. doi: 10.2147/COPD.S64491. eCollection 2014.

16.

Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease.

Inui N, Matsushima S, Kato S, Yasui H, Kono M, Fujisawa T, Enomoto N, Nakamura Y, Toyoshima M, Suda T.

Int J Chron Obstruct Pulmon Dis. 2015 Jun 17;10:1139-46. doi: 10.2147/COPD.S87058. eCollection 2015.

17.

Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients.

Mroz RM, Minarowski L, Chyczewska E.

Adv Exp Med Biol. 2013;756:23-8. doi: 10.1007/978-94-007-4549-0_4.

PMID:
22836615
18.
19.

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.

Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.

Thorax. 2015 Apr;70(4):311-9. doi: 10.1136/thoraxjnl-2014-206345. Epub 2015 Feb 12.

20.

Comparison of efficacy of long-acting bronchodilators in emphysema dominant and emphysema nondominant chronic obstructive pulmonary disease.

Fujimoto K, Kitaguchi Y, Kanda S, Urushihata K, Hanaoka M, Kubo K.

Int J Chron Obstruct Pulmon Dis. 2011;6:219-27. doi: 10.2147/COPD.S18461. Epub 2011 Apr 1.

Supplemental Content

Support Center